Neumora Therapeutics gets Nasdaq notice for falling below $1.00 bid price minimum

Neumora Therapeutics, Inc. disclosed in an 8-K filing that on October 26, 2026 it received a written notice from The Nasdaq Stock Market LLC stating the company is not meeting the minimum bid price rule of $1.00 required for continued listing on the Nasdaq Global Select Market under Listing Rule 5450(a)(1).¹

Under Nasdaq's rules, Neumora has 180 calendar days from the notice, running until April 26, 2027, to regain compliance, which requires its stock's closing bid price to reach or exceed $1.00 per share for at least ten consecutive business days within that window.¹

If the deadline passes without compliance, Neumora could seek additional time by applying to move its listing to The Nasdaq Capital Market, provided it meets that market's requirement for the value of publicly held shares and all other initial listing standards aside from the minimum bid price rule, along with paying an application fee and notifying Nasdaq of its plan to fix the deficiency.¹

Should the company fail to regain compliance within any permitted periods, Nasdaq would issue notice that the stock is subject to delisting, though Neumora would have the right to appeal that decision, with no guarantee Nasdaq would allow continued listing.¹

The company said it plans to keep watching its stock's closing bid price and weigh ways to address the shortfall, including the possibility of a reverse stock split.¹ Neumora also cautioned that there is no guarantee it will regain compliance with the bid price rule or stay compliant with other Nasdaq listing standards.¹

The filing was signed by Chief Financial Officer Michael Milligan on October 30, 2026.